Minakem and LibraGen Form Alliance in Biocatalysis and Fine Chemicals Production
News Nov 03, 2005
By jointly deploying their marketing and technical resources, the two companies will be able to deliver services and products to customers in many projects where there are synergies between fine chemicals production and biocatalysis.
LibraGen will use its proprietary META-DNA™ technology platform and know-how in applied biocatalysis to generate new biosynthesis routes that will be transferred to Minakem's cGMP compliant facilities for manufacturing.
“We are pleased to establish this partnership with LibraGen and provide additional technology opportunities to our customers, giving them direct access to chiral biocatalysis and Green Chemistry,” said Pierre Charrier, Business Development Director at Minakem.
“Minakem and LibraGen teams will together design innovative and efficient synthesis routes by combining LibraGen's unique skills in applied biocatalysis, and Minakem’s renowned expertise in chemical process development and FDA-approved chemical production facilities.”
“The joint operation will allow a very rapid implementation of the best performing production solutions. These will provide an excellent response to our customers’ budgetary and timeline requirements.”
“This alliance will bring LibraGen additional openings for providing its services to the fine chemicals and pharmaceuticals industry,” said Dr. Renaud Nalin, Chief Executive Officer at LibraGen.
“It is a great opportunity to provide pragmatic biocatalytic processes which, when combined with Minakem's chemistry and production capabilities, offer integrated solutions for the definition and the implementation of the best industrial production processes.”
“We will deploy all the technology available on our biocatalysis platform in these joint projects. This includes enzyme discovery, optimization and applied biocatalysis. We are looking forward to extending our market share through this alliance.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019